|Bid||141.06 x 800|
|Ask||142.58 x 1000|
|Day's range||138.09 - 142.69|
|52-week range||130.96 - 168.11|
|Beta (5Y monthly)||0.48|
|PE ratio (TTM)||38.90|
|Earnings date||07 Feb 2024 - 12 Feb 2024|
|Forward dividend & yield||6.20 (4.48%)|
|Ex-dividend date||12 Jan 2024|
|1y target est||154.21|
Shares of ImmunoGen (IMGN), a biotechnology company focused on cancer treatments, surged Thursday afternoon on news that pharmaceutical giant AbbVie (ABBV) plans to acquire the company in a deal valued around $10 billion. Yahoo Finance's Diane King Hall and Josh Lipton break down the details of the deal. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Data from a mid-stage study on AbbVie's (ABBV) experimental ADC drug demonstrates compelling clinical benefits across key endpoints in certain lung cancer patients.
Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.